Literature DB >> 12034057

Hemodynamic changes after levothyroxine treatment in subclinical hypothyroidism.

J Faber1, L Petersen, N Wiinberg, S Schifter, J Mehlsen.   

Abstract

In hypothyroidism, lack of thyroid hormones results in reduced cardiac function (cardiac output [CO]), and an increase of systemic vascular resistance (SVR). We speculated whether hemodynamic regulation in subjects with subclinical hypothyroidism (SH) (defined as mildly elevated thyrotropin [TSH] despite free thyroxine [T(4)] and triiodothyronine [T(3)] estimates within reference range) would benefit from levothyroxine (LT(4)) substitution. CO was measured by impedance cardiography, which is an observer independent method with high precision, and mean arterial pressure (MAP) by oscillometry. SVR was then calculated as MAP/CO. Measurements were performed before and after 60 degrees head-up tilting, and before and after LT(4) substitution. Plasma levels of catecholamines were also measured. In 16 otherwise healthy women with SH (ages 44-74 years; serum TSH in mean 17.1 mU/L (range, 6.8-27), and normal free T(4) and T(3) estimates) LT(4) treatment resulted in 6% reduction in supine MAP (p < 0.01), 14% increase in upright CO (p < 0.05), and 13%-20% decrease in SVR (supine and upright position, respectively) (p < 0.05). Plasma norepinephrine as well as epinephrine decreased during LT(4) treatment (p < 0.05). These changes were qualitatively similar but quantitatively less pronounced than in 15 women with overt hypothyroidism, also studied. Taking the two groups together (n = 31), pretreatment thyroid function (expressed as either TSH or free T(4) estimate) correlated to CO and SVR as well as the changes induced by LT(4) (p < 0.05), i.e., the lower the thyroid function the lower the CO and the higher the SVR, and the greater the response to LT(4). We conclude, that LT(4) treatment in SH results in changes in hemodynamic parameters of potentially beneficial character. SH and overt hypothyroidism should be regarded as a continuum, and our data favor earlier and more aggressive treatment of SH.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12034057     DOI: 10.1089/10507250252949450

Source DB:  PubMed          Journal:  Thyroid        ISSN: 1050-7256            Impact factor:   6.568


  6 in total

1.  Evaluation of Daily Blood Pressure Alteration in Subclinical Hypothyroidism.

Authors:  Ismail Polat Canbolat; Erdal Belen; Akif Bayyigit; Aysen Helvaci; Kadriye Kilickesmez
Journal:  Acta Cardiol Sin       Date:  2017-09       Impact factor: 2.672

Review 2.  Hypothyroidism as a risk factor for cardiovascular disease.

Authors:  Bernadette Biondi; Irwin Klein
Journal:  Endocrine       Date:  2004-06       Impact factor: 3.633

Review 3.  Subclinical thyroid disorders: the menace of the Trojan horse.

Authors:  L H Duntas
Journal:  J Endocrinol Invest       Date:  2003-05       Impact factor: 4.256

4.  Association Between Blood Pressure, Glomerular Filtration Rate, and Serum Thyroid-Stimulating Hormone Levels in Hypothyroid Patients: A Retrospective Single-Center Study.

Authors:  Manal O Alsulami; Nada M Alharbi; Dania W Alsulami; Sahar J Almaghrabi; Hadeel A Albaradei; Amani M Alhozali
Journal:  Cureus       Date:  2022-09-02

Review 5.  Understanding and managing toxicities of vascular endothelial growth factor (VEGF) inhibitors.

Authors:  Manuela Schmidinger
Journal:  EJC Suppl       Date:  2013-09

Review 6.  Cardiotoxicity with vascular endothelial growth factor inhibitor therapy.

Authors:  Rhian M Touyz; Joerg Herrmann
Journal:  NPJ Precis Oncol       Date:  2018-05-08
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.